

>Date: Fri, 26 Mar 2004 15:10:05 -0800

>From: Michael Belkin

http://biz.yahoo.com/prnews/040325/phth017_1.html

PR

Press ReleaseSource: Wyeth Pharmaceuticals

Wyeth Announces Discontinuation of Operations in Marietta, PA

Thursday March 25, 2004 12:00 pm ET

MADISON, N.J., March 25 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE - News), announced today that all operations at its Marietta, Pa. facility will be discontinued effective December 2004. The site was one of the primary manufacturing facilities for the company, focusing primarily on biologics and vaccines. Most recently, the site was primarily involved in manufacturing an investigational influenza vaccine. Final production of clinical trial materials for this vaccine will be completed later this year, at which time the facility will no longer be required for production. Wyeth's business partner will conduct future commercial production of this vaccine.

Today's announcement will result in a workforce reduction of approximately 440 employees. The company has notified its personnel at the site today and has outlined available severance packages as well as potential employment opportunities at other Wyeth sites. Workforce reductions are scheduled to begin at the site in mid-April.

Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth, has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, hemophilia, oncology, and vaccines. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery,

development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and nonprescription medicines that improve the quality of life for people worldwide. The company's divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

Source: Wyeth Pharmaceuticals